Merck, Fosamax Plaintiffs Clash Over Discovery

Law360, New York (May 31, 2008, 12:00 AM EDT) -- The plaintiffs in multidistrict litigation against Merck & Co. Inc. over osteoporosis drug Fosamax argued in a Manhattan courtroom Monday that the scope of discovery should be expanded, but Merck warned that granting the request would add to already-staggering costs.

U.S. District Judge John F. Keenan of the Southern District of New York heard arguments on the April 18 motion to compel Merck to comply with what the plaintiffs said were “legitimate and highly relevant” discovery requests.

The plaintiffs took issue with Merck's stance that it...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.